thejapantimes, 1 month ago to worldnews

Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's, Eisai and Biogen's Leqembi is facing an unexpected hurdle to widespread use. https://www.japantimes.co.jp/news/2024/04/24/world/science-health/alzheimer-drug-us-adoption-slow/ #worldnews #sciencehealth #alzheimers #brain #eisai #biogen #leqembi #us

jfballenger, 10 months ago to random

Dilemma: Will Leqembi ™ prolong quality of life, or more suffering?

"When FDA approves a new cancer agent, oncologists usually ask: will it prolong duration of good quality life, or just prolong duration of suffering, and will the side effects profile be tolerable enough whether it works or not?

"Those kinds of questions seem pertinent to the new Alzheimer’s Disease (AD) medication, lecanemab, marketed now as Leqembi ™. "

#alzheimer #lecanemab #leqembi
https://caregivingoldguy.website/2023/08/07/dilemma-will-leqembi-tm-prolong-quality-of-life-or-more-suffering/

stevesilberman, 10 months ago to random

Big news! I have a new column in Scientific American, for which I'm deeply grateful. The first one is on how my mother's #dementia showed me another side of #neurodiversity. Rough stuff, but the state of eldercare in the US is horrific. Please spread this link. https://www.scientificamerican.com/article/how-my-mothers-dementia-showed-me-another-side-of-neurodiversity/?utm_campaign=socialflow&utm_source=twitter&utm_medium=social